Ignite Creation Date:
2024-05-06 @ 2:20 PM
Last Modification Date:
2024-10-26 @ 1:29 PM
Study NCT ID:
NCT04284761
Status:
COMPLETED
Last Update Posted:
2024-06-24
First Post:
2020-02-12
Brief Title:
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Sponsor:
Alessa Therapeutics Inc
Organization:
Alessa Therapeutics Inc
Study Overview
Official Title:
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Biolen-PC
Brief Summary:
Biolen a novel implant is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease while minimizing systemic exposure and its associated side-effects The objectives of the study are to assess whether the Biolen is safe
Detailed Description:
This prospective multi-center single-arm feasibility study is planned to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate in patients presenting for treatment of prostate cancer Study participants will have placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None